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Whole Body CT Imaging in Deceased Donor 
Screening for Malignancies
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Michiel E. Erasmus, MD, PhD,4 Jeroen de Jonge, MD, PhD,5 Kirsten M.  de Vries, MSc,2  
Michel F. van der Jagt, MD,6 Niels P. van der Kaaij, MD, PhD,7 Marcel C.G. van de Poll, MD, PhD,8,9 
Ian P.J. Alwayn, MD, PhD,1 and Andries E. Braat, MD, PhD1
Organ transplantation improves quality of life and increases life expectancy of patients with end-stage 
organ failure but is limited by a shortage of available organs. 
In the Netherlands and in most European countries, the wait-
ing list for organ transplantation increases. The number of 
available organs is relatively stable over the past years, but 
the median donor age is increasing.1 To increase the amount 
of available organs extended criteria donors are being used, 
taking a risk on inferior results achieved compared with nor-
mal organ donors.2 For example, by increasing donor age 
selection criteria, organ quality may decrease and the risk 
of malignancy in the donor increases.3 In case of an active 
malignancy, the patient is often not eligible for organ dona-
tion, depending on type and location of the tumor.4 Despite 
extensive donor screening, donor-derived malignancies have 
been reported.5–8 Other incidental findings which may exclude 
Organ Donation and Procurement
Background. In most western countries, the median donor age is increasing. The incidence of malignancies in older 
populations is increasing as well. To prevent donor-derived malignancies we evaluated radiologic donor screening in a ret-
rospective donor cohort. Methods. This study analyzes the efficacy of a preoperative computed tomography (CT) scan 
on detecting malignancies. All deceased organ donors in the Netherlands between January 2013 and December 2017 
were included. Donor reports were analyzed to identify malignancies detected before or during organ procurement. Findings 
between donor screening with or without CT-scan were compared. Results. Chest or abdominal CT-scans were per-
formed in 17% and 18% of the 1644 reported donors respectively. Screening by chest CT-scan versus radiograph resulted 
in 1.5% and 0.0% detected thoracic malignancies respectively. During procurement no thoracic malignancies were found in 
patients screened by chest CT compared with 0.2% malignancies in the radiograph group. Screening by abdominal CT-scan 
resulted in 0.0% malignancies, compared with 0.2% in the abdominal ultrasound group. During procurement 1.0% and 1.3% 
malignancies were found in the abdominal CT-scan and ultrasound groups, respectively. Conclusions. Screening by 
CT-scan decreased the perioperative detection of tumors by 30%. A preoperative CT-scan may be helpful by providing addi-
tional information on (aberrant) anatomy to the procuring or transplanting surgeon. In conclusion, donor screening by CT-scan 
could decrease the risk of donor-derived malignancies and prevents unnecessary procurements per year in the Netherlands.
(Transplantation Direct 2019;5: e509; doi: 10.1097/TXD.0000000000000953. Published online 15 November, 2019.)
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organs from transplantation are hepatic steatosis or cirrhosis, 
pancreatic fibrosis, renal atrophy, or extensive bilateral lower 
lobe atelectasis. Some benign and incidental findings, such as 
a single uncomplicated kidney cyst or mild hepatic steato-
sis, are usually no objection for transplantation.4 For assess-
ing donor suitability, different characteristics are taken into 
account, such as medical history, cause of death, demographic 
characteristics, laboratory tests, and imaging studies. The fol-
lowing imaging studies are part of the current protocol in 
donor screening in the Eurotransplant (ET) Region; abdomi-
nal ultrasound (US), chest radiograph, and occasionally bron-
choscopy.4 In the event of an inconclusive result, additional 
tests may be performed such as histopathologic examination.
An alternative for standard donor screening by chest radi-
ograph and abdominal US is to perform a computed tomog-
raphy (CT) scan of chest and abdomen. Malignancies have 
a higher probability of being detected with a CT-scan com-
pared with a chest radiograph or abdominal US alone. The 
risk of donor-derived malignancies in organ transplantation 
can never be excluded completely, but prevention should be 
pursued given the very poor prognosis in the recipients when 
transmission has occurred with a <50% 2 year survival in 
certain malignancies.7 A potential downside of increasing the 
number or frequency of medical imaging is the risk of creat-
ing uncertainty by incidental findings.9–11 Incidental findings 
such as a simple renal, thyroid, or hepatic cyst might not be 
a contraindication to refrain from transplantation but could 
unnecessary delay or even abort the donation procedure. And 
by performing chest/abdominal CT-scans the costs of donor 
screening will in all likelihood increase slightly. A recent case 
with a donor-derived malignancy drew a lot of negative media 
attention in the Netherlands.8 Therefore, the aim of this study 
is to analyze the added effect of abdominal and thoracic CT 
scans in the prevention of donor-derived malignancies.
MATERIALS AND METHODS
Data Analysis
In this retrospective analysis, all patients reported to ET as 
organ donor in the Netherlands between January 1, 2013 and 
December 31, 2017 were included. Baseline characteristics 
were collected from the ET Network Information System from 
ET and Organ Procurement Information database from the 
Dutch Transplant Foundation. Donor reports were analyzed 
for any change in organ allocation outcome based on results 
of radiologic diagnostics or malignancies found during organ 
procurement. Reported donors without any documented medi-
cal imaging were excluded from the analysis. When both imag-
ing modalities were documented (thoracic CT-scan and chest 
radiograph or abdominal CT-scan and abdominal US), the 
donor was included in the CT-scan group. If no CT-scan was 
reported, the donors were included in the chest radiograph only 
or abdominal US only group. When a (possible) malignancy 
was detected by imaging, the donor report was analyzed. If the 
(possible) malignancy was detected by abdominal US or chest 
radiograph, the donor was included in standard imaging group. 
If the (possible) malignancy was detected by the CT-scan alone, 
the donor was included in the CT-scan group.
Statistical Analysis
To assess the distribution of the data histograms as well 
as Shapiro-Wilk tests were used. Differences in categorical 
data were assessed by using the Chi-Square test. To compare 
skewed continuous data the Mann-Whitney U was used. P < 
0.05 was considered statistically significant. Continuous data 
were presented as mean ± SD and categorical data as abso-
lute number (%) unless otherwise stated. For statistical analy-
sis IBM SPSS Statistics for Windows was used (IBM Corp. 
Released 2016. Version 24.0. Armonk, NY).
RESULTS
Data Analysis
A total of 1644 organ donors were reported of which 
1546 donors were approved for donation of at least 1 organ. 
This resulted in 1316 donor procurements leading to 1270 
effectuated donor procedures of which at least 1 organ was 
transplanted. Donor characteristics stratified for thoracic 
and abdominal imaging are presented in Table 1 and Table 2. 
Chest CT-scans or radiographs were performed in 274 (17%) 
and 996 (61%) of the 1644 potential donors, respectively. 
Of the 274 potential donors with a thoracic CT-scan, in 207 
(75%) potential donors a chest radiograph was made as well. 
Abdominal CT-scans or USs were performed in 296 (18%) 
and 1197 (73%) of the 1644 potential donors, respectively. 
Of the 296 potential donors with an abdominal CT-scan, 
in 114 (40%) potential donors an abdominal US was made 
as well. In 374 (23%) donors no thoracic and in 154 (9%) 
donors no abdominal radiologic screening was documented 
and hence were excluded from the analysis. Of all reported 
DCD donors, 984 of 1005 (98%) were type III DCD donors. 
Euthanasia (according to the Dutch law) was performed in 
9 of 1005 (1%) donors (DCD type V) and 12 of 1005 were 
type I or type II DCD donors. The type I and II DCD donors 
were evaluated for kidney donation alone during a clinical 
trial. As shown in Tables 1 and 2, more CT-scans were per-
formed in young donors and in the CT-scan group trauma 
was the most common cause of death. Of all donors with 
trauma as cause of death, 6 of 300 donors (2.0%) were diag-
nosed with a malignancy during procurement. A chest- or 
abdominal CT-scan was performed in 55% and 52% of all 
these donors, respectively. Of the donors with a nontrau-
matic cause of death, 23 of 1344 donors (1.7%) were diag-
nosed with a malignancy before or during procurement. A 
chest- or abdominal CT-scan was performed in 14% and 
12% of all these donors, respectively. In 286 (17%) organ 
donors, only the kidneys were procured.
Thoracic and Abdominal Screening
Screening by an additional chest CT-scan versus chest radi-
ograph only resulted in, respectively, 1.5% and 0% detection 
of (possible) thoracic malignancies (Table  3). During pro-
curement, no additional thoracic malignancies were found in 
donors screened by chest CT compared with 0.2% in the chest 
radiograph only group. Screening by abdominal CT-scan ver-
sus US resulted in, respectively, 0.0% and 0.2% detection of 
(possible) abdominal malignancies (Table 3). During procure-
ment, in 1.0% of the potential donors additional abdominal 
malignancies were found in donors screened by abdominal 
CT-scan compared with 1.3% in the US only group. Notably, 
3 hearts and 5 lungs were already transplanted by the thoracic 
transplant team, while later on an abdominal malignancy 
was detected during abdominal organ procurement. Of these 
donors, no abnormalities were seen on the chest radiograph 
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or abdominal US before procurement. No CT-scan was per-
formed in these donors. The malignancies of the donors were 
diagnosed after procurement of the thoracic organs and dur-
ing or after transplantation of the thoracic organs in the recip-
ients. In the Netherlands, first the thoracic organs are being 
procured by the thoracic transplant surgeons. After this, the 
abdominal organs are procured by a certified procurement 
surgeon, not necessarily being a transplant surgeon. To mini-
mize the cold ischemic time, most of the time the recipient of 
the heart or lungs is being prepared for transplantation while 
procurement of the abdominal organs is not yet finished and 
the results of the pathology are not known. With a mean fol-
low-up of 2 years, no donor-derived malignancy was reported 
in these transplanted patients.
Malignancies Detected Before and During 
Procurement
Tables 4 and 5 show all (possible) malignancies detected 
before and during procurement. Not every suspected finding 
was biopsied before procurement. The thoracic abnormalities 
were detected by chest CT-scan only and not by chest radio-
graph. The abdominal abnormalities were detected by US only 
or US and CT-scan, as shown in Table 4. Of the possible tho-
racic malignancies detected before procurement, 2 abnormali-
ties could not be biopsied for histopathologic examination. 
Histopathologic evaluation of the other 2 thoracic abnormali-
ties showed 1 malignant and 1 benign finding. The abdominal 
US of donor 5 (Table 4) showed multiple hypoechoic lesions 
with a possible halo sign. The CT-scan performed after the US 
confirmed multiple lesions with enhanced uptake of arterial 
contrast without evidence for wash-out in the venous phase. 
The most likely diagnosis was focal nodular hypertrophy or 
hepatic adenomatosis, but metastases could not be excluded 
completely. A perioperative biopsy showed focal nodular 
hypertrophy and the organs could be transplanted safely. The 
abdominal US of donor 6 (Table 4) showed an interlobular 
cysts of which the biopsy resulted in a renal cell carcinoma. 
If a malignancy was detected during procurement, all proce-
dures were canceled, except for the already procured thoracic 
organs as explained before.
DISCUSSION
This study shows the potential benefit of extended radio-
logic screening in deceased organ donation. Screening by 
CT-scan decreased the percentages of perioperative detec-
tion of tumors, from 0.2% to 0% for thoracic CT-scans, and 
from 1.3% to 1.0% for abdominal CT-scans. This resulted 
in a relative risk reduction of 30% for perioperative detec-
tion of malignancies by thoracic and abdominal screening 
with CT-scan. Interestingly, in the traumatic younger patients, 
more often a CT-scan was performed. But the malignancies 
detected by CT-scan before procurement (Table  4) were all 
in nontraumatic patients. This could be explained by the 
fact that younger donors have an increased risk for trauma 
as cause of death and a decreased risk for malignancy. 
Furthermore, the evaluation of a CT-scan made for screen-
ing in trauma patients is more focused on traumatic injuries, 
so malignancies could be missed during the initial evaluation. 
Implementing CT-scan in the standard donor screening proto-
col could prevent ~7 unnecessary procurement procedures in 
5 years in the Netherlands. To detect 1 abdominal or thoracic 
malignancy, 235 CT-scans must be made. In this donor cohort, 
3 hearts and 5 lungs were already transplanted by the tho-
racic transplant team when later on a malignancy (lung, renal 
or pancreas carcinoma) was found by the abdominal organ 
procurement team. It is to be expected that this could have 
been prevented if an additional CT-scan had been performed. 
And despite the apparently good outcome in these cases until 
now, such risks must be avoided at all times. Besides careful 
surgical evaluation of the thoracic and abdominal cavity, we 
suggest a CT-scan could be of additional value. Some possible 
malignancies detected during screening by chest radiograph, 
abdominal US or CT-scan turned out to be no malignancy 
after all. Therefore it is of utmost importance to assess the 
abnormalities by histopathologic evaluation. In 2016, Tache 
et al12 published the results of their study to analyze the role of 
chest/abdominal CT-scan in donor selection and preoperative 
TABLE 1.
Donor characteristics of reported donors, stratified for 
thoracic imaging
Chest  
CT-scan
Chest  
radiograph P
Number of reported donors 274 (17%) 996 (61%)  
Female 115 (42%) 466 (46.8%) 0.156
Age 49.6 (17.2) 53.0 (14.5) 0.027
Cause of death    
 CVA 77 (28%) 581 (58%) <0.001
 Trauma 125 (46%) 102 (10%) <0.001
 Other 72 (26%) 313 (31%) 0.101
DCD donation 158 (58%) 559 (56%) 0.649
Kidney-only procurement 37 (14%) 128 (13%) 0.776
CT, computed tomography; CVA, cerebrovascular accident; DCD, donation after circulatory death.
TABLE 2.
Donor characteristics of reported donors, stratified for 
abdominal imaging
Abdominal 
CT-scan
Abdominal 
US P
Number of reported donors 296 (18%) 1197 (73%)  
Female (%) 106 (36%) 562 (47%) 0.001
Age 49.0 (18.3) 54.2 (14.4) <0.001
Cause of death    
 CVA 85 (29%) 651 (54%) <0.001
 Trauma 148 (50%) 135 (11%) <0.001
 Other 63 (21%) 411 (34%) <0.001
DCD donation 182 (61%) 712 (60%) 0.529
Kidney-only procurement 57 (19%) 200 (17%) 0.298
CT, computed tomography; CVA, cerebrovascular accident; DCD, donation after circulatory death; 
US, ultrasound.
TABLE 3.
Number of (possible) malignancies detected before and 
during procurement
Before  
procurement
During  
procurement
Chest CT-scan 4 (1.5%) 0
Chest radiograph 0 2 (0.2%)
Abdominal CT-scan 0 3 (1.0%)
Abdominal US 2 (0.2%) 15 (1.3%)
CT, computed tomography; US, ultrasound.
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planning of the organ procurement strategy in brain dead 
organ donors. Organ procurement was not performed in 22 
(24%) donors because of general contraindications, in 12 
of 22 cases additional findings (diffuse thromboatheroma-
tous disease, 1 hydatid cyst and 10 possible malignancies) 
detected by a CT-scan alone, were reason to refrain from the 
donor procedure. Of the 68 potential organ donors accepted 
for donation, 11 organs (16%) were not procured based on 
CT-findings alone. Aberrant vascular anatomy was detected 
in the hepatic or renal vasculature in 10% and 28% of the 
patients, respectively. The study concluded with a strong rec-
ommendation to further implement donor screening by use of 
a chest and abdominal CT-scan.12 In 2017, Bethier et al per-
formed a prospective study to assess the role of whole body 
CT-scan for determining morphologic suitability for organ 
donation in brain dead patients.13 Radiologic findings of 
CT-scans were compared with perioperative findings and/or 
the result of histopathologic analysis of biopsy specimens. The 
study concluded that during procurement 4 of 12 lesions, of 
which biopsies were obtained during procurement, were not 
visible during procurement but had been detected by CT-scan 
preoperatively. Vascular anatomic variants were seen in the 
hepatic or renal vasculature in 8% and 33% of the potential 
donors respectively. By providing anatomical information to 
the surgeon, identifying relevant lesions not immediately vis-
ible intraoperatively and effectively identifying anomalies as 
contraindication to donation, this study also confirms the value 
of extended screening by use of a CT-scan.13 In a retrospective 
study, Bozovic et al analyzed the outcome of extended imag-
ing in 110 potential lung donors.14 All chest radiograph and 
(in-)complete CT examinations were collected and reviewed 
from a donation perspective. In 13 potential donors a com-
plete chest CT-scan was performed and in 29 CT examina-
tions of other body parts included a part of the lungs as well. 
Compared with the chest radiograph group, more relevant 
information for lung transplantation was obtained in the CT 
group. These findings consisted of anatomic variations and 
organ size of importance for preoperative planning, pulmo-
nary edema that may be suitable for ex vivo reconditioning, 
emphysema, aspiration, lymphadenopathy due to systemic 
disease, infections or malignancies. Even more important, 
pulmonary emboli and malignancies were identified before 
procurement, both absolute contraindications for lung dona-
tion. Some of the findings, such as sarcoidosis or anatomical 
TABLE 4.
Type and location of (possible) malignancies detected before procurement
# Suspected anomaly Imaging made Detected by Pathology Outcome
1 Suspected lung nodules Chest-CT Chest-CT No biopsy taken No procurement
2 Suspected lung nodules Chest-CT and chest radiograph Chest-CT No biopsy taken No procurement
3 Suspected lung nodules Chest-CT Chest-CT Biopsy during procurement, no malignancy Organs transplanted
4 Suspected lung nodules Chest-CT and chest radiograph Chest-CT Biopsy during procurement, lung carcinoma No procurement
5 Liver abnormalities Abdominal US and abdominal CT Abdominal US and abdominal CT Biopsy during procurement, no malignancy Organs transplanted
6 Kidney abnormalities Abdominal US Abdominal US Biopsy before procurement, renal cell carcinoma No procurement
CT, computed tomography; US, ultrasound.
TABLE 5.
Type and location of malignancies detected during procurement
# Affected organ Imaging made Detected by Pathology confirmed
1 Lung Chest radiograph Procurement Adenocarcinoma; primary
2 Lung Chest radiograph Procurement Adenocarcinoma; metastases
3 Spleen Abdominal CT-scan Procurement Lymphoma
4 Pancreas Abdominal CT-scan Procurement Neuroendocrine tumor
5 Liver Abdominal CT-scan (haemangioma seen) Procurement Hepatocellular carcinoma
6 Kidney Abdominal US Procurement Renal cell carcinoma
7 Kidney Abdominal US Procurement Multiple benign tumors, not transplantable due to quality
8 Kidney Abdominal US Procurement Renal cell carcinoma
9 Kidney Abdominal US Procurement Renal cell carcinoma
10 Kidney Abdominal US Procurement Renal cell carcinoma
11 Kidney Abdominal US Procurement Renal cell carcinoma
12 Kidney Abdominal US Procurement Renal cell carcinoma
13 Kidney Abdominal US Procurement Renal cell carcinoma
14 Liver Abdominal US Procurement Liver metastases
15 Large intestine Abdominal US Procurement Colon carcinoma
16 Small intestine Abdominal US Procurement Neuroendocrine tumor
17 Enlarged abdominal lymph nodes Abdominal US Procurement Malignancy not to be excluded
18 Pancreas Abdominal US Procurement Malignancy not to be excluded
19 Pancreas Abdominal US Procurement Pancreas carcinoma
20 Pancreas Abdominal US Procurement Pancreas carcinoma
21 Pancreas Abdominal US Procurement No malignancy
CT, computed tomography; US, ultrasound.
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variants, could be of importance for heart transplantation as 
well. Based on all findings this study suggests a more promi-
nent role of CT in the screening of deceased lung donors.14
In modern surgical practice, no major abdominal surgery 
is planned or performed without adequate radiologic imag-
ing. The criteria and considerations for the screening of living 
donors is for a large part comparable with deceased donor 
screening.4 Screening of living kidney donors with a CT-scan 
provides the surgeon with precise preoperative anatomy of the 
kidney, thus reducing the risks and complications associated 
with the procurement procedure and identifying preoperative 
factors that might even preclude living kidney donation.15,16
A possible disadvantage of applying more extensive imag-
ing is the risk of incidental findings and false-positive errors, 
resulting in unnecessary cancelation of the donation pro-
cedure before the implication of the findings are properly 
assessed. In 2005 Beinfeld et al showed a sensitivity between 
63% and 94% and a specificity between 63% and 93% to 
detect malignancies by nonenhanced CT-scans, resulting in 
false negative and false positive errors, respectively.17 Because 
not every detected abnormality was sent for histopathologic 
evaluation in this study, no false negative or positive errors 
can be calculated. Development of uniform guidelines on how 
to deal with incidental findings in deceased donor screening 
is crucial. Nonetheless, the evolution and development of 
imaging modalities over the last couple of decades is exten-
sive. Although image modalities are sophisticated, continuous 
improvement and refinement are expected to further dimin-
ishing the harmful effects and errors.
The risk of acute kidney failure as result of contrast-
induced nephropathy could be addressed as a negative effect 
of extended donor imaging by enhanced CT-scans. However, 
recent studies in high risk patients (estimated Glomerular 
Filtration Rate 30-59 mL/min) showed no difference in con-
trast induced nephropathy between prophylactic and nonpro-
phylactic hydrated group. None of the 660 patients required 
hemodialysis within 35 days after administration.18 Donors 
eligible for kidney donation are patients with an adequate 
creatinine clearance, thus being less at risk compared with 
patients with a known kidney disease and impaired kidney 
function.19 In the last years, a change in practice has occurred 
within the transplant community, resulting in an increase of 
using contrast media enhanced examinations.20 Although cau-
tion is still advised, the effects are much less severe than was 
previously assumed.
In 2018, the reimbursement by health insurance compa-
nies in the Netherlands for chest radiograph, abdominal US, 
enhanced chest, and abdominal CT-scan was €42, €117, €183, 
and €194, respectively.21 Calculating extra reimbursements 
for CT-scans of all reported donors results in ~€66 000 per 
year. Performing a CT-scan only in potential donors with age 
≥45 years would cost €53 250 per year. In this donor cohort, 
the youngest donor diagnosed with a malignancy before or 
during procurement was 45 years old. We acknowledge these 
data consists of really small numbers and does not justify set-
ting any age limit, but generally speaking older donors do 
have an increased risk on malignancy. If only focusing on 
malignancy screening, as performed in this study, it could be 
a possibility to only perform a CT-scan in older donors. If 
more information is needed on organ anatomy and vascula-
ture, no age limit should be set. From an ethical perspective, 
if less invasive ways are available to assess donor suitability 
and organ quality, this cannot be ignored before organ pro-
curement. Considering the poor prognosis of donor-derived 
malignancies, all efforts should be made to prevent this. 
Furthermore, by identifying possible contraindications before 
procurement, it shortens the duration of a donation procedure 
and hereby decreases the emotional burden for the relatives of 
the donor. With increasing healthcare expenses and shortage 
of specialized personnel, it is of utmost importance to utilize 
these scarce resources. If contraindications are known before 
procurement procedure, it could save energy, time and money 
by canceling the procurement procedure.
This study has a few limitations that need to be addressed. 
First, this retrospective Dutch donor cohort has many missing 
data on aberrant vascular anatomy and subsequent outcomes 
after procurement. Radiologic imaging was made for clinical 
purposes, often not evaluated for donor screening and sub-
sequently not systematically reevaluated for anatomical and 
vascular variances. Although these data would be a valuable 
addition to this study, several previous studies have already 
addressed this topic and its clinical relevance on transplant 
outcome.12–16 Second, there is a difference between the per-
centage of malignancies published in studies on deceased 
donor screening (7%–11%) and our cohort of Dutch reported 
donors.12–14 Before reporting a potential donor to ET, the 
transplant coordinator performs an in depth analysis of the 
medical report of the potential donor. Donors with a known 
active malignancy were likely not to be reported to ET and 
thus excluded for donation. Previous studies on deceased 
donor screening included all brain dead patients admitted 
to the Intensive Care Unit, and this selection bias could par-
tially explain the difference between the reported percentages. 
Another possible explanation for the difference in the percent-
age of malignancies detected in this study could be the result 
of kidney-only donation. During procurement of kidney-only 
donors, the thoracic organs are not exposed and evaluated. If 
not detected by chest radiograph, thoracic malignancies could 
be missed during procurement of the kidneys. Third and last, 
studies performed on CT-imaging in deceased donor screening 
lack a control group for comparison. No studies are avail-
able that compared conventional screening with CT-scans 
and the corresponding perioperative findings. Nonetheless, 
previous studies and our study showed relevant findings by a 
CT-scan, probably not detected by conventional imaging.12–14 
With increasing incidence of obesity in the general popula-
tion, abdominal US screening capacities might be limited by 
donor weight.22
This study shows an increased detection of malignancies by 
CT-scan before organ procurement compared with the stand-
ard radiologic screening. If a CT-scan would have been made 
of all potential organ donors, 7 unnecessary procurements 
could be prevented in the Netherlands in the last 5 years. 
Another potential benefit could be the additional information 
on (aberrant) vasculature, organ size, and quality. In conclu-
sion, screening by CT-scan results in an increased detection 
of malignancies before procurement by 30%, thereby increas-
ing patient safety for the recipient and decreasing the risk on 
donor-derived malignancy.
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